Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity.
This letter describes the development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved aqueous solubility (approximately 18 mg/mL) that translates into enhanced cell activity and caspase-3 induction.